ClinicalTrials.gg
CompletedNCT07558044KET-TONSILUpdated May 5, 2026

Ketamine Gargle for Pain After Pediatric Tonsillectomy

A Phase 4 interventional study of Ketamine Hydrochloride in saline and Normal Saline (0.9% NaCl) in Postoperative Pain, Tonsillectomy and Adenotonsillectomy, sponsored by Hospital Universitario de Caracas. Completed at 1 site in Venezuela. Open to participants aged 4 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Hospital Universitario de Caracas · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2026).
Phase
Phase 4
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Study summary

Post-tonsillectomy pain in children is a common and clinically significant problem that may lead to poor oral intake, dehydration, and delayed recovery. This study evaluates whether a simple preoperative intervention-gargling with ketamine-can reduce postoperative pain and improve recovery after pediatric adenotonsillectomy.

In this randomized, double-blind, placebo-controlled trial, 420 children aged 4 to 12 years undergoing elective adenotonsillectomy were assigned to receive either a ketamine gargle (40 mg in saline) or a saline placebo prior to anesthesia induction. Pain intensity was measured using the Visual Analog Scale at multiple time points within the first 24 hours after surgery. Secondary outcomes included postoperative bleeding requiring reintervention, analgesic consumption, and adverse events.

The study aims to determine whether topical ketamine provides effective and safe analgesia as part of an opioid-sparing strategy in pediatric airway surgery.

Read the detailed description

Adenotonsillectomy is one of the most frequently performed surgical procedures in pediatric patients and is associated with significant postoperative pain. Effective analgesia remains challenging due to the need to balance efficacy with safety, particularly avoiding opioid-related respiratory complications. Topical ketamine, a non-competitive NMDA receptor antagonist, has been proposed as a peripheral analgesic strategy capable of reducing nociceptive signaling without significant systemic effects.

This study was designed as a prospective, randomized, double-blind, placebo-controlled trial conducted at a tertiary care center. A total of 420 pediatric patients (ASA I-II, aged 4-12 years) scheduled for elective adenotonsillectomy were enrolled. Participants were randomized in a 1:1 ratio to receive either a ketamine gargle (40 mg diluted in 30 mL saline) or a placebo saline gargle administered 5 minutes before induction of anesthesia.

All patients underwent standardized anesthetic and surgical protocols to minimize confounding variables. Pain intensity was assessed using the Visual Analog Scale at 0, 4, 8, 12, and 24 hours postoperatively. Secondary outcomes included incidence of postoperative hemorrhage requiring surgical reintervention, total rescue analgesic consumption, and adverse events such as nausea, vomiting, sedation, or psychomimetic effects.

The primary objective was to evaluate the analgesic efficacy of preemptive topical ketamine. Secondary analyses explored its potential impact on postoperative morbidity, particularly bleeding events. This study was conducted in accordance with ethical standards and CONSORT guidelines.

02

Conditions studied

  • Postoperative Pain
  • Tonsillectomy
  • Adenotonsillectomy

Browse trials for

Keywords

  • ketamine gargle
  • pediatric anesthesia
  • postoperative analgesia
  • NMDA receptor antagonist
  • opioid-sparing analgesia
  • airway surgery
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's enrollment of 420 is above the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Hospital Universitario de Caracas is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Children aged 4-12 years
  • I-II
  • Scheduled for elective adenotonsillectomy
  • Ability to gargle and spit the study solution

Exclusion Criteria:

  • Known to ketamine
  • Coagulation disorders
  • History of neuropsychiatric disease
  • Active upper respiratory tract infection

Exclusion Criteria:

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    KETAMINE GROUP

    Preoperative gargle with 40 mg ketamine diluted in 30 mL saline, administered 5 minutes before induction of anesthesia.

    Drug: Ketamine Hydrochloride in saline · Other: Normal Saline (0.9% NaCl)

  • Experimental
    PLACEBO GROUP

    Preoperative gargle with 30 mL normal saline administered 5 minutes before induction.

    Drug: Ketamine Hydrochloride in saline · Other: Normal Saline (0.9% NaCl)

Interventions

  • DrugKetamine Hydrochloride in saline

    Ketamine gargle at a dose of 40mg diluted in 30 mL of normal saline, administered 5 minutes before induction of anesthesia. Patients were instructed to gargle the solution for 30 seconds and then expectorate.

  • OtherNormal Saline (0.9% NaCl)

    Placebo gargle consisting of 30 mL of normal saline, administered 5 minutes before induction of anesthesia. Patients were instructed to gargle the solution for 30 seconds and then expectorate.

06

What researchers measure

Primary outcomes

  1. Postoperative pain intensity

    Pain intensity measured using the Visual Analog Scale (VAS; 0-10) at predefined postoperative time points.

    Time frame: 0, 4, 8, 12, and 24 hours postoperatively

Secondary outcomes

  1. Postoperative hemorrhage requiring surgical reintervention

    Incidence of postoperative bleeding requiring return to the operating room for hemostasis.

    Time frame: Within 24 hours postoperatively

  2. Rescue analgesic consumption

    Total requirement of additional analgesics (e.g., paracetamol or NSAIDs) within the first 24 hours after surgery.

    Time frame: 24 hours postoperatively

  3. Adverse events

    Incidence of postoperative nausea and vomiting, sedation, or psychomimetic effects such as hallucinations or dysphoria.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • VERAZA
    Caracas, Miranda 1040, Venezuela
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data (IPD) sharing has not yet been determined. Data may be made available upon reasonable request to the corresponding author following publication, in accordance with institutional policies and applicable ethical regulations.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07558044
Lead sponsor
Hospital Universitario de Caracas
Responsible party
Joseph Alejandro Veraza Almeida (Staff of Anesthesiology Department, Hospital Universitario de Caracas) — Principal investigator
First posted
Apr 30, 2026
Start date
Jan 10, 2024
Primary completion
Jan 7, 2025
Completion
Jan 14, 2025
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion